156 related articles for article (PubMed ID: 17371699)
1. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA
Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699
[TBL] [Abstract][Full Text] [Related]
2. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
5. Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists.
Cowart M; Faghih R; Gfesser G; Curtis M; Sun M; Zhao C; Bennani Y; Wetter J; Marsh K; Miller TR; Krueger K; Pan JB; Drescher K; Fox GB; Esbenshade TA; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S25-6. PubMed ID: 15928820
[No Abstract] [Full Text] [Related]
6. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD
J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
8. Histamine H3 receptor antagonists: from target identification to drug leads.
Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T
Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
10. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
Altenbach RJ; Liu H; Banfor PN; Browman KE; Fox GB; Fryer RM; Komater VA; Krueger KM; Marsh K; Miller TR; Pan JB; Pan L; Sun M; Thiffault C; Wetter J; Zhao C; Zhou D; Esbenshade TA; Hancock AA; Cowart MD
J Med Chem; 2007 Nov; 50(22):5439-48. PubMed ID: 17918921
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of A-960656, a histamine H₃ receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain.
Cowart M; Hsieh G; Black LA; Zhan C; Gomez EJ; Pai M; Strakhova M; Manelli A; Carr T; Wetter J; Lee A; Diaz G; Garrison T; Brioni JD
Eur J Pharmacol; 2012 Jun; 684(1-3):87-94. PubMed ID: 22504024
[TBL] [Abstract][Full Text] [Related]
14. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
15. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
[TBL] [Abstract][Full Text] [Related]
16. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
Hancock AA; Bennani YL; Bush EN; Esbenshade TA; Faghih R; Fox GB; Jacobson P; Knourek-Segel V; Krueger KM; Nuss ME; Pan JB; Shapiro R; Witte DG; Yao BB
Eur J Pharmacol; 2004 Mar; 487(1-3):183-97. PubMed ID: 15033391
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent benzofuran histamine H(3) receptor antagonists with sub-nanomolar potency.
Cowart M; Gfesser GA; Bhatia K; Esser R; Sun M; Miller TR; Krueger K; Witte D; Esbenshade TA; Hancock AA
Inflamm Res; 2006 Apr; 55 Suppl 1():S47-8. PubMed ID: 16705379
[No Abstract] [Full Text] [Related]
18. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
19. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
[TBL] [Abstract][Full Text] [Related]
20. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
